BofA Securities recently highlighted Centene (CNC) as a potential earnings outlier, pointing to a projected rebound in Medicaid margins by 2029 that could reshape how investors think about the company’s profit profile.

The recent BofA commentary lands at a time when momentum in Centene’s stock has picked up, with a 30 day share price return of 51.91% and a 90 day share price return of 36.77%, even though the 5 year total shareholder return is down 19.65%.

If this shift in sentiment around managed care has your attention, it could be a good moment to widen your watchlist and look at 33 healthcare AI stocks

So, with Centene trading just above the average analyst price target but carrying a large implied intrinsic discount, is the recent rebound already fully reflected in the stock, or is the market underestimating its potential for future growth?

Most Popular Narrative: 7.6% Overvalued

Centene's most followed narrative points to a fair value of $54.94, which sits below the last close of $59.14 and frames the recent rally in a more cautious light.

Analysts expect earnings to reach $2.7 billion (and earnings per share of $5.67) by about May 2029, up from $6.4 billion of losses today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $3.5 billion in earnings, and the most bearish expecting $2.4 billion.

The entire narrative hangs on a sharp earnings reset, modest revenue growth, and a future profit multiple below many healthcare peers. Want to see how those moving pieces fit together and what assumptions need to hold for that fair value to stick?

Result: Fair Value of $54.94 (OVERVALUED)

However, that hinges on policy staying relatively supportive. Any setback on Medicaid rate adequacy or a sustained spike in medical and specialty drug costs could quickly challenge it.

Another View: Multiples Paint A Very Different Picture

While the analyst narrative points to Centene being 7.6% overvalued versus a fair value of $54.94, the current pricing on sales tells a sharply different story. The stock trades on a P/S ratio of just 0.2x, compared with 1.6x for peers, 1.2x for the wider US Healthcare group, and a fair ratio of 0.8x.

If the market were to move closer to that fair ratio, it would indicate a level of optimism that is not currently reflected in the price. The question is whether you think today’s cautious sentiment or that potential re rating better reflects the balance of risks.

Next Steps

If the mixed signals on Centene have you torn, this is the moment to look at the numbers, weigh the risks, and act on your own view. To see what others are optimistic about, take a closer look at the 3 key rewards.

Looking for more investment ideas?

If Centene has sharpened your focus, do not stop here. Use the Simply Wall St Screener to spot other stocks that could fit your portfolio goals.

• Target resilience by scanning companies with strong finances and low risk scores through the 64 resilient stocks with low risk scores.
• Hunt for potential bargains by checking the 52 high quality undervalued stocks that combine solid cash flows with quality fundamentals.
• Spot opportunities off the radar by reviewing the screener containing 20 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.